Clinical trials: Chemoradiotherapy
Locally Advanced Salivary Gland Carcinoma
Prospective Registry Study on the Implementation of Simultaneous Postoperative Radiochemotherapy for Salivary Gland Carcinomas of the Head and Neck Region
This is a prospective registry study based on a standard therapy concept for postoperative simultaneous radiochemotherapy established in Erlangen and elsewhere.
- Trial name
- NCT06464198
- Testing
- simultaneous postoperative radiochemotherapy
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Glioblastoma
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted…
- Trial name
- PRIDE (NCT05871021)
- Testing
- Dose escalation of radiation dose beyond the therapeutic standard
- Where
- 9 sites in Germany
- Volunteers
- 107 people
- Sponsor
- University Hospital Tuebingen
Non-small Cell Lung Cancer
Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy
This study proposes to evaluate the safety and efficacy of an anti-PD-L1 (durvalumab) agent as neoadjuvant therapy in patients diagnosed with localized NSCLC who are planned to undergo radical RT or CRT.
- Trial name
- IDEAR (NCT05267392)
- Testing
- Durvalumab, standard of care RT/RCT
- Where
- Portugal
- Volunteers
- 30 people
- Sponsor
- Instituto Portugues de Oncologia, Francisco Gentil, Porto
Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
This phase I trial studies the side effects, best dose, and best way to give pembrolizumab when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-IIIB non-small cell lung…
- Conditions
- Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT02621398
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Rutgers, The State University of New Jersey
Endometrial Cancer
Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- PORTEC-3 (NCT00411138)
- Testing
- Radiation Therapy, cisplatin, carboplatin
- Where
- Netherlands
- Volunteers
- 670 people
- Sponsor
- Leiden University
Cholangiocarcinoma
Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma
The study evaluates impact of high dose radiation on overall survival in patients with unresectable nonmetastatic cholangiocarcinoma.
- Trial name
- NCT02773485
- Testing
- High Dose Radiation, Systemic chemotherapy
- Where
- India
- Volunteers
- 155 people
- Sponsor
- Tata Memorial Hospital
NSCLC, Stage III
Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
This is a Prospective, open, single arm study to evaluate the efficacy and safety of the almonertinib combined with concurrent chemoradiotherapy in unresectable stage III NSCLC with EGFR mutation
- Trial name
- NCT04952168
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Yuan Chen
Oesophageal Adenocarcinoma, Squamous Cell Carcinoma
M6620 Plus Standard Treatment in Oesophageal and Other Cancer
This Phase I study will test the combination of a novel ATR inhibitor (M6620) with chemoradiotherapy in oesophageal cancer; utilizing three experimental cohorts (Stage A1, A2 and B).
- Conditions
- Oesophageal Adenocarcinoma, Squamous Cell Carcinoma, Solid Tumor
- Trial name
- CHARIOT (NCT03641547)
- Testing
- M6620, Cisplatin, Capecitabine
- Where
- 5 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- University of Oxford
Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma
Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
This Phase II trial evaluates the efficacy and safety of Serplulimab combined with S1 chemotherapy in patients with inoperable, locally advanced esophageal squamous cell carcinoma after concurrent chemoradiation.
- Trial name
- Stars (NCT06422858)
- Testing
- Serplulimab, Tegafur-gimeracil-oteracil potassium capsule(S1), Radiotherapy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Zhejiang Cancer Hospital
Rectal Cancer
Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer
RATIONALE: Preoperative 5-Fu based chemoradiation has become standard treatment for stage 2/3 rectal cancer. However whether these patients, especially T3N0-1M0 patients, really need radiation for local control after total…
- Trial name
- FOWARC (NCT01211210)
- Testing
- fluorouracil, fluorouracil, oxaliplatin
- Where
- China
- Volunteers
- 495 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer
Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer
Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) is now considered as a standard treatment of locally advanced rectal adenocarcinomas, which correlates better local control and higher sphincter preservation rate.
- Trial name
- NCT01899118
- Testing
- Preoperative irradiation, Nimotuzumab, Oxaliplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer, Adenocarcinoma
Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients
The aim of this study is to evaluate the efficacy of a neoadjuvant approach in patients with locally advanced gastric cancer and the identification of prognostic factors.
- Conditions
- Gastric Cancer, Adenocarcinoma, Effects of Chemotherapy, Surgery
- Trial name
- NCT02454647
- Testing
- Induction chemotherapy, Radiotherapy with concurrent chemotherapy, Salvage surgery
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Head and Neck Squamous Cell Carcinoma (HNSCC), Locally Advanced Head and Neck Squamous Cell Carcinoma
[18F]-AraG PET Imaging in LA HNSCC
This study will use [18F]-AraG PET/CT scans to monitor patients who have been diagnosed with locally advanced Head and Neck Squamous Cell carcinoma (LA-HNSCC), and are planning to undergo standard of care chemoradiotherapy for…
- Trial name
- NCT07168785
- Testing
- [18F]-AraG radiotracer, Chemotherapy, Radiotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Indiana University
Cervical Squamous Cell Carcinoma
Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma
To investigate the efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy in the treatment of local advanced cervical squamous cell carcinoma.
- Trial name
- NCT04678791
- Testing
- Nimotuzumab, Cisplatin, External-beam radiation
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Peking University Third Hospital
Rectal Cancer
Dosimetric Limitation of Pelvic Bone and Peritoneal Space in Rectal Cancer Patients During Chemoradiotherapy
This project first retrospectively analyzes the intestinal dose indicators related to the concurrent radiotherapy and chemotherapy of rectal cancer and gastrointestinal toxicity, and the pelvic dose indicators related to…
- Trial name
- NCT05688033
- Testing
- dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma
The standard treatment strategy of locally advanced nasopharyngeal carcinoma (NPC) nowadays is concurrent chemoradiation (CCRT) based on intensity-modulated radiation therapy (IMRT).
- Trial name
- NCT02512315
- Testing
- Docetaxel (DOC), Cisplatin (DDP), Concurrent chemoradiation (CCRT)
- Where
- 4 sites in China
- Volunteers
- 192 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Oropharyngeal Carcinoma
Thermotherapy for Head and Neck Cancer Patients
This phase I, single-center study evaluates the safety, tolerability, and recommended phase II dose (RP2D) of mild hyperthermia (thermotherapy) when added to standard-of-care treatment in patients with locally advanced head and…
- Conditions
- Head and Neck Cancer, Oropharyngeal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma
- Trial name
- TANCAP-I (NCT07690618)
- Testing
- Thermotherapy, Radiotherapy, Concurrent chemoradiation
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Erasmus Medical Center
Locally Advanced Nasopharyngeal Carcinoma
Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma
This trial is a multi-center phase III clinical trial. The purpose of this trial is to explore whether 2 cycles induction chemotherapy combined with concurrent chemoradiotherapy is not inferior to 3 cycles induction chemotherapy…
- Trial name
- NCT05860868
- Testing
- 2 cycles induction chemotherapy, 3 cycles induction chemotherapy
- Where
- China
- Volunteers
- 474 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Esophageal Squamous Cell Carcinoma
Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus
The purpose of this study is to determine which regimen is better for esophageal squamous carcinoma in concurrent chemoradiation(CCRT),paclitaxel or S1 plus cisplatin.
- Trial name
- NCT02586753
- Testing
- Paclitaxel plus Cisplatin with radiotherapy, S1 plus Cisplatin with radiotherapy
- Volunteers
- 2 people
- Sponsor
- Mianyang Central Hospital
Rectal Neoplasms
Fish Oil Supplement in Rectal Cancer
Neoadjuvant treatment with radiotherapy (RDT) and chemotherapy (CT) are the treatment of choice for rectal adenocarcinomas in stages II and III. This results currently in pathologic complete response in 10% to 30% of cases.
- Trial name
- NCT02534389
- Testing
- omega-3 fish oil
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.